Abstract: A phase-locked loop (PLL) is implemented to have another (second) PLL in place of the controlled oscillator. When a known frequency change in the frequency of the output clock is desired, in addition to changing a configuration of the PLL (first PLL), the configuration of the second PLL is also changed to cause the frequency of the output clock to change quickly. In various embodiments, the configuration of the second PLL is changed by changing the divisor of the feedback divider of the second PLL, the divisor in a pre-scaler in the second PLL, the control voltage of a VCO used in the second PLL, and any other point of user control in the second PLL.

Abstract: A scalable data feed system is disclosed. The data feed system may be offered as a cloud service that can serve many enterprises or tenants that require data to be pulled from information sources such as FTP, POP3, databases, line of business systems, a topic subscription, or an RSS feed, and pushed the data to information sinks, such as SMTP, email, FTP, mobile phones, and other devices and services. A pull agent pumps data from pull sources and pushes the data out to push agent counterparts. The push agent transforms and sends the data in messages to push sink, such as FTP, SMTP, or a mobile device. Both the pull agent and the push agent services are implemented as replicated services over a structured overlay network for high availability that can serve multiple requests to pump out data from multiple pull sources and push the data to multiple information sinks.

Abstract: An external surface for a fastener insert to be embedded in a component includes waterfall threads extending along an outer surface of the portion to be embedded. The waterfall thread includes a first portion and a second portion, the first portion being more axially oriented on the surface than the second portion, and the second portion being more circumferentially oriented on the surface than the first portion. Continuous transitions are provided between adjacent first and second portions in a thread.

Abstract: An external surface for a fastener insert to be embedded in a component includes waterfall threads extending along an outer surface of the portion to be embedded. The waterfall thread includes a first portion and a second portion, the first portion being more axially oriented on the surface than the second portion, and the second portion being more circumferentially oriented on the surface than the first portion. Continuous transitions are provided between adjacent first and second portions in a thread.

Abstract: A scalable data feed system is disclosed. The data feed system may be offered as a cloud service that can serve many enterprises or tenants that require data to be pulled from information sources such as FTP, POP3, databases, line of business systems, a topic subscription, or an RSS feed, and pushed the data to information sinks, such as SMTP, email, FTP, mobile phones, and other devices and services. A pull agent pumps data from pull sources and pushes the data out to push agent counterparts. The push agent transforms and sends the data in messages to push sink, such as FTP, SMTP, or a mobile device. Both the pull agent and the push agent services are implemented as replicated services over a structured overlay network for high availability that can serve multiple requests to pump out data from multiple pull sources and push the data to multiple information sinks.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: A scalable data feed system is disclosed. The data feed system may be offered as a cloud service that can serve many enterprises or tenants that require data to be pulled from information sources such as FTP, POP3, databases, line of business systems, a topic subscription, or an RSS feed, and pushed the data to information sinks, such as SMTP, email, FTP, mobile phones, and other devices and services. A pull agent pumps data from pull sources and pushes the data out to push agent counterparts. The push agent transforms and sends the data in messages to push sink, such as FTP, SMTP, or a mobile device. Both the pull agent and the push agent services are implemented as replicated services over a structured overlay network for high availability that can serve multiple requests to pump out data from multiple pull sources and push the data to multiple information sinks.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: A scalable data feed system is disclosed. The data feed system may be offered as a cloud service that can serve many enterprises or tenants that require data to be pulled from information sources such as FTP, POP3, databases, line of business systems, a topic subscription, or an RSS feed, and pushed the data to information sinks, such as SMTP, email, FTP, mobile phones, and other devices and services. A pull agent pumps data from pull sources and pushes the data out to push agent counterparts. The push agent transforms and sends the data in messages to push sink, such as FTP, SMTP, or a mobile device.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: The present invention relates to a process for the preparation of a water soluble inclusion complex of neem seed kernel extract (NSKE) containing azadirachtin-A in cyclodextrin and its use in an insecticidal formulation. The process of the present invention comprises the following steps adding neem seed kernel extract containing azadirachtin-A to cyclodextrin, the molar ratio of azadirachtin-A to the cyclodextrin ranging from 1:0.5 to 1:20, stirring the above mixture, filtering the above mixture to obtain a water soluble inclusion complex of neem seed kernel extract, if desired, freeze/spray drying the said water soluble complex of neem seed kernel extract to get a free flowing pale cream powder.